TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16222890

Group type: EXPERIMENTAL
Intervention: 0.2 mg tamsulosin once daily orally (n = 40)
Number of subjects: 76

Group type: COMPARATOR
Intervention: 10 mg alfuzosin once daily orally (n = 36)
Number of subjects: 76
Study: 11507926

Group type: EXPERIMENTAL
Intervention: Sodium hexametaphosphate dentifrice
Number of subjects: 96

Group type: COMPARATOR
Intervention: High-abrasive dentifrice
Number of subjects: 96

Group type: COMPARATOR
Intervention: Marketed control dentifrice
Number of subjects: 96
Study: 10102945

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d., clarithromycin 500 mg b.d., amoxycillin 1 g b.d.
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., amoxycillin 1 g b.d.
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.d., clarithromycin 500 mg b.d., amoxycillin 1 g b.d.
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d., tetracycline 500 mg t.d.s., tinidazole 500 mg b.d.
Number of subjects: 278
Study: 7757313

Group type: EXPERIMENTAL
Intervention: Antipyrine powder (1,050 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Antipyrine capsule (1,050 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Antipyrine powder and capsule formulations
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Antipyrine capsule formulation
Number of subjects: 12
Study: 2148194

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 228
Study: 37697

Group type: EXPERIMENTAL
Intervention: Clopimozide (average optimum daily dose of 13.95 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31232917

Group type: EXPERIMENTAL
Intervention: MLH1-negative circulating tumor cells
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Total circulating tumor cells (CTCs)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MLH1-negative CTCs
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mesenchymal markers-expressing CTCs
Number of subjects: 32
Study: 28381198

Group type: EXPERIMENTAL
Intervention: Ticagrelor combined with aspirin
Number of subjects: 952

Group type: COMPARATOR
Intervention: Clopidogrel combined with aspirin
Number of subjects: 952
Study: 25471821

Group type: EXPERIMENTAL
Intervention: Decision-making with more involvement than desired by the patient
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Decisions made with clinicians whose decision-making style preference was for more active involvement than the patient preference
Number of subjects: 445
Study: 23851776

Group type: EXPERIMENTAL
Intervention: Merocel applied directly for 24 hours
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Merocel applied directly for 48 hours
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Merocel kept in a glove finger for 24 hours
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Merocel kept in a glove finger for 48 hours
Number of subjects: 129
Study: 21737787

Group type: EXPERIMENTAL
Intervention: 1×10(5) cells/kg of mobilized autologous CD34+ cells
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo (equal volume of diluent)
Number of subjects: 167
Study: 19929767

Group type: EXPERIMENTAL
Intervention: Ventilator‐induced hyperinflation using pressure support ventilation in sidelying
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sidelying
Number of subjects: 30
Study: 16738150

Group type: EXPERIMENTAL
Intervention: Primary overlap repair
Number of subjects: 64

Group type: COMPARATOR
Intervention: End-to-end repair
Number of subjects: 64
Study: 15129073

Group type: EXPERIMENTAL
Intervention: CD-Horizon (CD-H)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Moss Miami (MM)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: TSRH
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: ISOLA
Number of subjects: 127
Study: 11124134

Group type: EXPERIMENTAL
Intervention: Triglyceride (Intralipid 20%, 1.5 ml/min) and heparin (bolus: 200 IU; constant infusion rate: 0.2 IU.kg(‐1).min(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 10
Study: 9767201

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 0
Study: 10381989

Group type: EXPERIMENTAL
Intervention: Ipratropium with beta-agonists
Number of subjects: 1377
Study: 2239170

Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (GAGPS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 408145

Group type: EXPERIMENTAL
Intervention: Hydrochloric acid
Number of subjects: 15

Group type: COMPARATOR
Intervention: Protein-rich meal
Number of subjects: 15
Study: 30232824

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon (PEB)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 88
Study: 28194595

Group type: EXPERIMENTAL
Intervention: Double-Balloon Colonoscopy (DBC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional Colonoscopy (CC)
Number of subjects: 18
Study: 26307622

Group type: EXPERIMENTAL
Intervention: Postexposure prophylaxis (PEP) for consensual sexual activity
Number of subjects: 3200

Group type: COMPARATOR
Intervention: Traditional methods
Number of subjects: 3200

Group type: EXPERIMENTAL
Intervention: Combined methods
Number of subjects: 3200

Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP)
Number of subjects: 3200
Study: 24074299

Group type: EXPERIMENTAL
Intervention: Online psychological treatment
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 1000
Study: 22041670

Group type: EXPERIMENTAL
Intervention: Remnant preservation (RP) group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 19780352

Group type: EXPERIMENTAL
Intervention: NaF fluoridated Ca‐free water
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Naturally fluoridated hard water
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Artificially fluoridated soft water
Number of subjects: 60
Study: 16762124

Group type: EXPERIMENTAL
Intervention: Course in motivational interviewing
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no course)
Number of subjects: 3
Study: 15574072

Group type: EXPERIMENTAL
Intervention: Strength training for quadriceps and hamstring muscles
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no strength training)
Number of subjects: 22
Study: 11318061

Group type: EXPERIMENTAL
Intervention: Up-right/down-left mapping with left response initiating action
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Up-right/down-left mapping with right response initiating action
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Up-right/down-left mapping with both keypresses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Up-right/down-left mapping with both spoken location names
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Up-right/down-left mapping with one spoken location name and one keypress
Number of subjects: 0
Study: 9463667

Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 287

Group type: COMPARATOR
Intervention: Oral iron treatment
Number of subjects: 287

Group type: COMPARATOR
Intervention: Malaria chemoprophylaxis after discharge
Number of subjects: 287
Study: 8193499

Group type: EXPERIMENTAL
Intervention: Soy-based formula (Isomil)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cow's milk formula (SMA)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study: 2574555

Group type: EXPERIMENTAL
Intervention: Terfenadine, 60 mg bid
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 25 mg qid
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 30919459

Group type: EXPERIMENTAL
Intervention: TCu380Ag
Number of subjects: 600
Study: 30117448

Group type: EXPERIMENTAL
Intervention: Vestibular stimulation (swinging back to front)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (no vestibular stimulation)
Number of subjects: 240
Study: 26188234

Group type: EXPERIMENTAL
Intervention: Telemonitoring group (TG)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 105
Study: 23767790

Group type: EXPERIMENTAL
Intervention: Fermented milk
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21269305

Group type: EXPERIMENTAL
Intervention: Minocycline (MINO) for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roxithromycin (RXM) for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faropenem (FRPM) for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no oral antibiotics for 4 weeks)
Number of subjects: 0
Study: 18185995

Group type: EXPERIMENTAL
Intervention: KEEP (Keeping Foster Parents Trained and Supported) based on Multidimensional Treatment Foster Care (MTFC)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 700
Study: 16877984

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg) combined with IV propofol (0.5 mg/kg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: IV propofol alone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral midazolam combined with IV propofol
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 54
Study: 12780361

Group type: EXPERIMENTAL
Intervention: High winning expectancies
Number of subjects: 34

Group type: COMPARATOR
Intervention: Low winning expectancies
Number of subjects: 34
Study: 10966534

Group type: EXPERIMENTAL
Intervention: D-Dimer levels measured at admission to the ED
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: D-Dimer level >500 microg/L
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Fibrinogen levels measured at admission to the ED
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Other hemostatic markers (thrombin‐antithrombin complexes, prothrombin fragment 1+2, activated factor VII)
Number of subjects: 257
Study: 8941062

Group type: EXPERIMENTAL
Intervention: 2.5 mg/d MPA plus 0.625 mg/d conjugated estrogens (group A: 31 patients)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 0.625 mg/d estrone sulfate (group B: 28 patients)
Number of subjects: 59
Study: 1609752

Group type: EXPERIMENTAL
Intervention: 1.4 mg Zn/d
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 2.5 mg Zn/d
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 3.4 mg Zn/d
Number of subjects: 11

Group type: COMPARATOR
Intervention: 10.4 mg Zn/d
Number of subjects: 11
Study: 4001840

Group type: EXPERIMENTAL
Intervention: In vitro challenge with foods or food antigens on mucosal specimens
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intragastric food challenge
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: In vitro challenge
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Radioallergosorbent and skin tests
Number of subjects: 15
Study: 31468596

Group type: EXPERIMENTAL
Intervention: Lycopene 25 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 29167971

Group type: EXPERIMENTAL
Intervention: Abaloparatide-SC 20 μg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Abaloparatide-SC 40 μg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Abaloparatide-SC 80 μg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Subcutaneous teriparatide 20 μg
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 26201835

Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (400 U)
Number of subjects: 259

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 259
Study: 23756850

Group type: EXPERIMENTAL
Intervention: Combined therapy (prednisolone + lamivudine)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Monotherapy (prednisolone)
Number of subjects: 46
Study: 22040285

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) intervention consisting of three 2-hr group sessions scheduled during a single week.
Number of subjects: 133

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 133
Study: 20227241

Group type: EXPERIMENTAL
Intervention: web‐based therapist‐assisted cognitive behavioral treatment (web‐CBT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: waiting‐list control
Number of subjects: 58
Study: 17765381

Group type: EXPERIMENTAL
Intervention: 50 mg of dimenhydrinate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15804686

Group type: EXPERIMENTAL
Intervention: Complete smoking cessation (abstainers)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Smoking reduction (reducers)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Continuation of usual smoking (continuing smokers)
Number of subjects: 220
Study: 12512792

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment protocol as defined by consensus among acupuncture trainers
Number of subjects: 14
Study: 10329342

Group type: EXPERIMENTAL
Intervention: 30 continuous minutes of brisk walking
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Three 10‐minute bouts of brisk walking
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 30 minutes of brisk walking in any combination of bouts (minimum 5 minutes each)
Number of subjects: 32
Study: 7866989

Group type: EXPERIMENTAL
Intervention: HMFG1 (IgG1 radiolabeled anti-mucin mAb)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (4D513 isotype-matched control)
Number of subjects: 29
Study: 1742749

Group type: EXPERIMENTAL
Intervention: L-threonine 4.5 g/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: L-threonine 6.0 g/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6891929

Group type: EXPERIMENTAL
Intervention: Prednisolone 5 mg b.d. (P)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Ovarian irradiation (O)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Tamoxifen 10 mg b.d. (T)
Number of subjects: 204
Study: 30724701

Group type: EXPERIMENTAL
Intervention: Weighted Jacket (WJ)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Eccentrically Loaded Dumbbell (LDB)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Countermovement Jump (CMJ)
Number of subjects: 29
Study: 28142296

Group type: EXPERIMENTAL
Intervention: Probiotic capsule
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27065056

Group type: EXPERIMENTAL
Intervention: P2Y12-receptor specific assay (ADPtest HS)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard ADP assay (ADPtest)
Number of subjects: 400
Study: 24685414

Group type: EXPERIMENTAL
Intervention: Standard Regimen + individualized homeopathic medicine (SR + H)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard Regimen + identical placebo (SR + P)
Number of subjects: 120
Study: 22515945

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cold-water-induced DNIC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined tDCS and DNIC
Number of subjects: 15
Study: 19039231

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy to maintain strict normoglycemia (below 110 mg/dl)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strict blood glucose control with intensive insulin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strict blood glucose control
Number of subjects: 0
Study: 18088216

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) delivered in school or clinic settings by trained clinicians
Number of subjects: 700
Study: 15333734

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) with high isoflavone content (mean intake 96 mg/d)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Soy protein isolate (SPI) with low isoflavone content (mean intake 6 mg/d)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High isoflavone intake in hypercholesterolemic subjects
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High isoflavone intake in normocholesterolemic subjects
Number of subjects: 8
Study: 11441210

Group type: EXPERIMENTAL
Intervention: Constraint-induced (CI) aphasia therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional aphasia therapy
Number of subjects: 17
Study: 9459258

Group type: EXPERIMENTAL
Intervention: Clonidine 5 microg/kg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Clonidine 2.5 microg/kg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (0 microg/kg)
Number of subjects: 61
Study: 7972189

Group type: EXPERIMENTAL
Intervention: New dressing for digit injuries
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional digit dressings
Number of subjects: 0
Study: 2541985

Group type: EXPERIMENTAL
Intervention: Guar gum (6.6 g/bar, average consumption 31.7 g/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo bar (no guar gum)
Number of subjects: 16
Study: 31691181

Group type: EXPERIMENTAL
Intervention: Social ties (affective, personal, and professional ties) rated on a 5-point Likert scale
Number of subjects: 272

Group type: COMPARATOR
Intervention: Clinical experience, demographics, and knowledge of team roles
Number of subjects: 272
Study: 28340136

Group type: EXPERIMENTAL
Intervention: TAJ-Plus (with added class smoke-free pledge)
Number of subjects: 433

Group type: COMPARATOR
Intervention: TAJ (Triple A in Jordan)
Number of subjects: 433
Study: 26356698

Group type: EXPERIMENTAL
Intervention: Exercise training (8-week supervised program of endurance and resistance exercise)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control
Number of subjects: 188
Study: 23930712

Group type: COMPARATOR
Intervention: Diet A (control) - 6.4g lysine per 100g CP
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Diet B - 4.5g lysine per 100g CP
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Diet B
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Diet A
Number of subjects: 432
Study: 21118735

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg/d and Amoxicillin 1000 mg BID plus Esomeprazole 20 mg BID (group A)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg/d and Amoxicillin 1000 mg BID plus Esomeprazole 40 mg BID (group B)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg/d and Amoxicillin 1000 mg BID plus Rabeprazole 10 mg BID (group C)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype effect on eradication rates
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 184
Study: 18230244

Group type: EXPERIMENTAL
Intervention: moxifloxacin (MFX)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: gatifloxacin (GFX)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: ofloxacin (OFX)
Number of subjects: 217

Group type: COMPARATOR
Intervention: isoniazid (INH), pyrazinamide and rifampicin (RMP) with either ethambutol, GFX, MFX or OFX
Number of subjects: 217
Study: 16368293

Group type: EXPERIMENTAL
Intervention: Methotrexate (7.5 mg once a week, n = 35)
Number of subjects: 71
Study: 15753186

Group type: EXPERIMENTAL
Intervention: Fish oil plus different doses of vitamin E for 3 months
Number of subjects: 0
Study: 10992331

Group type: EXPERIMENTAL
Intervention: H‐ORS (245 mmol/liter)
Number of subjects: 170
Study: 9030787

Group type: EXPERIMENTAL
Intervention: Blunt dissection
Number of subjects: 32

Group type: COMPARATOR
Intervention: Transthoracic en-bloc resection (EB)
Number of subjects: 32
Study: 8130297

Group type: EXPERIMENTAL
Intervention: R (simple relaxation)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: REMG (R + EMG biofeedback)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: BP (BP biofeedback only)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: RBP (R + BP)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control Group (TA, reading about transactional analysis without skills training)
Number of subjects: 117
Study: 3773599

Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Combination of dipyrone, pitofenone and fenpipramide (control)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 43
Study: 29516425

Group type: EXPERIMENTAL
Intervention: Topical fusidic acid (2%) and recombinant human interferon after ALA-PDT
Number of subjects: 718

Group type: COMPARATOR
Intervention: Recombinant human interferon (control group)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Fusidic acid group (for PDT-associated infection)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Mupirocin group (for PDT-associated infection)
Number of subjects: 718
Study: 27404516

Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FSO)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Corn oil (CO)
Number of subjects: 59
Study: 24944063

Group type: COMPARATOR
Intervention: 0 egg yolks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1 egg yolk
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2 egg yolks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 4 egg yolks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 6 egg yolks
Number of subjects: 6
Study: 22939358

Group type: EXPERIMENTAL
Intervention: Chlorthalidone combined with azilsartan medoxomil
Number of subjects: 609

Group type: COMPARATOR
Intervention: Hydrochlorothiazide combined with azilsartan medoxomil
Number of subjects: 609
Study: 20028948

Group type: EXPERIMENTAL
Intervention: Exercise training (12-week combined progressive training program, 3 times per week, 45 min per session)
Number of subjects: 38
Study: 19016941

Group type: EXPERIMENTAL
Intervention: BIMS (Brief Interview of Mental Status) administered by research assistants
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: BIMS (Brief Interview of Mental Status) administered by facility nurses
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: BIMS for any impairment (3MS<78)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: BIMS for severe impairment (3MS<48)
Number of subjects: 374